1. Scrip

Straggler Novavax Still Hopes To Hit Paydirt With Combo Vaccine

 
• By Alaric DeArment

The company announced early data for a combination vaccine against SARS-CoV-2 and influenza, which could provide a revenue opportunity of $2bn.

Novavax Trial US
Novavax is aiming for a potentially $2bn opportunity with its SARS-CoV-2/influenza combination vaccine • Source: Getty Images

Novavax, Inc. had hoped NVX-CoV2373 could be a third COVID-19 vaccine option in the US after Pfizer Inc./BioNTech SE’s Comirnaty and Moderna, Inc.’s Spikevax, but due to a series of stumbles, that has yet to materialize. However, even in a market that the two messenger RNA vaccines have come to dominate, the company could still have a shot at a blockbuster opportunity with new data on a combination vaccine against COVID-19 and influenza, as well as the potential to address the market for adolescents.

The company announced 22 April that it started a vaccine booster study among adolescents as part of its Phase III...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Pipeline Watch: ASCO Dominates Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Sanofi’s Blueprint buy; AstraZeneca’s breast cancer resistance results at ASCO; BMS and BioNTech’s big bispecific deal; Kymera’s Dupixent in a pill; and Degron’s CEO on pipeline and strategy.

Chinese Biotech VC/PE Fundings Rise But Still Modest

 
• By Dexter Jie Yan

LTZ Therapeutics and Beijing Sungen Biomedical are among the Chinese biotechs raising new funding, of around $40m each, based on their clinical assets with novel mechanisms of action. While fundings have risen, they remain moderate however.